CV Sciences' President and Chief Executive Officer, Michael Mona, Jr. and Chief Financial Officer, Joseph Dowling, will lead the call to provide shareholders and prospective investors information highlighting the Company's most recent updates and accomplishments during 2017. They will also address the Company's strategic initiatives moving forward.

In order to ensure adequate time for any software downloads that may be necessary to listen to the webcast, attendees are encouraged to connect to the website prior to the live event. Participants may also access the call by dialing 1-877-407-8293 (United States) or 1-201-689-8349 (International).

If you are unable to participate in the call at the time of the live event, a replay will be available for 14 days starting on September 13, 2017, at approximately 7:30AM PT/10:30 AM ET. To access the replay, please dial 877-877-660-6853 in the U.S. and 201-612-7415 for international callers. The conference ID# is 13670027.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.